Maze Therapeutics' Loss Widens To $48 Million As Its Experimental Drug Programs Cost More
Maze expects its $477 million cash and investment balance to fund operations into 2029, with kidney drug results due in early 2027.
Maze Therapeutics, which develops experimental oral medicines for kidney and metabolic diseases, posted a third-quarter loss of $48.0 million, widening from $30.1 million a year earlier as drug development and personnel costs increased. Monday's results, released with an SEC filing, also showed a larger cash and investment balance that management expects to fund operations into 2029.
More Spending, More Cash
Research and development spending reached $40.2 million for the quarter, versus $25.2 million a year earlier. Maze attributed the increase primarily to work on MZE829 and MZE782 and higher personnel costs, including non-cash stock compensation.
Administrative expenses rose to $11.3 million from $7.8 million, primarily because of personnel costs, including stock compensation, and professional services. The unaudited quarterly loss was $0.79 per share, compared with $0.66 a year earlier.
For the first nine months, research spending was $109.3 million versus $80.9 million, while administrative spending reached $36.8 million versus $24.0 million. Net loss widened to $116.9 million from $96.6 million, but loss per share declined to $2.02 from $2.45; the weighted-average share count was 57,944,856, compared with 39,464,634.
Cash, cash equivalents and investments totaled $477.0 million at September 30, up from $360.0 million at year-end 2025. Maze's funding forecast into 2029 rests on its current business plan.
Kidney Trial Outruns Enrollment Target
Maze has completed enrollment in its mid-stage MZE829 trial, with more than 50 patients across three groups. The experimental medicine targets APOL1-mediated kidney disease, a form of chronic kidney disease that Maze estimates affects more than one million people in the United States.
Enrollment “exceeded our target enrollment of 10-15 patients per cohort,” Maze Chief Executive Officer Jason Coloma said in the earnings release. The groups cover patients with diabetes, patients without diabetes and patients with focal segmental glomerulosclerosis, a kidney disease.
Previously reported interim findings showed reductions in a measure of protein leakage into urine after 12 weeks among 12 patients whose results could be evaluated for efficacy. Those preliminary results are background to the full dataset Maze expects in early 2027. The company plans a pivotal trial in the first half of 2027, subject to regulatory feedback.
MZE782 And A Shionogi Milestone
Maze uses human genetics and its Compass platform to identify disease-linked variants and select drug targets. Its wholly owned programs center on MZE829 and MZE782, while partnerships provide another source of revenue.
License revenue was zero for the quarter, as it was a year earlier. For the first nine months, it totaled $20.0 million versus zero, from a first-quarter milestone under the Shionogi license for MZE001, an experimental Pompe disease treatment designed to limit glycogen buildup.
MZE782 is being tested in a mid-stage trial for phenylketonuria, an inherited metabolic disorder. Earlier healthy-volunteer testing showed a 42-fold increase in phenylalanine removal through urine; enrollment in the patient trial is ongoing, with results expected in 2027.
Maze also plans a kidney trial for MZE782 in the first half of 2027 to assess reductions in protein leakage into urine.
The complete MZE829 dataset expected in early 2027 will inform Maze's planned pivotal program, Coloma said.
Sources
- 8-K Filing — Maze Therapeutics, Inc. (MAZE) — SEC EDGAR
- Exhibit maze-ex99_1.htm — Maze Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Maze Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- Maze Therapeutics to Participate in Upcoming Investor — globenewswire.com